348 related articles for article (PubMed ID: 28112970)
1. Clinical use of PI3K inhibitors in B-cell lymphoid malignancies: today and tomorrow.
Greenwell IB; Flowers CR; Blum KA; Cohen JB
Expert Rev Anticancer Ther; 2017 Mar; 17(3):271-279. PubMed ID: 28112970
[TBL] [Abstract][Full Text] [Related]
2. PI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma.
Lampson BL; Brown JR
Expert Opin Investig Drugs; 2017 Nov; 26(11):1267-1279. PubMed ID: 28945111
[TBL] [Abstract][Full Text] [Related]
3. Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma.
Yang Q; Modi P; Newcomb T; Quéva C; Gandhi V
Clin Cancer Res; 2015 Apr; 21(7):1537-42. PubMed ID: 25670221
[TBL] [Abstract][Full Text] [Related]
4. Idelalisib for relapsed/refractory indolent B-cell non-Hodgkin's lymphoma: an overview of pharmacokinetics and clinical trial outcomes.
Davies A
Expert Rev Hematol; 2015 Oct; 8(5):581-93. PubMed ID: 26343890
[TBL] [Abstract][Full Text] [Related]
5. Idelalisib for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma.
Barrientos JC
Future Oncol; 2016 Sep; 12(18):2077-94. PubMed ID: 27324214
[TBL] [Abstract][Full Text] [Related]
6. Idelalisib for treatment of B-cell malignancies.
Do B; Mace M; Rexwinkle A
Am J Health Syst Pharm; 2016 Apr; 73(8):547-55. PubMed ID: 26933132
[TBL] [Abstract][Full Text] [Related]
7. Idelalisib.
Zirlik K; Veelken H
Recent Results Cancer Res; 2018; 212():243-264. PubMed ID: 30069634
[TBL] [Abstract][Full Text] [Related]
8. Idelalisib- a PI3Kδ targeting agent for B-cell malignancies.
Hewett YG; Uprety D; Shah BK
J Oncol Pharm Pract; 2016 Apr; 22(2):284-8. PubMed ID: 25712626
[TBL] [Abstract][Full Text] [Related]
9. Haematological cancer: idelalisib-targeting PI3Kδ in patients with B-cell malignancies.
Burger JA; Okkenhaug K
Nat Rev Clin Oncol; 2014 Apr; 11(4):184-6. PubMed ID: 24642682
[TBL] [Abstract][Full Text] [Related]
10. PI3K Inhibitors: Understanding Toxicity Mechanisms and Management.
Greenwell IB; Ip A; Cohen JB
Oncology (Williston Park); 2017 Nov; 31(11):821-8. PubMed ID: 29179250
[TBL] [Abstract][Full Text] [Related]
11. CAL-101: a phosphatidylinositol-3-kinase p110-delta inhibitor for the treatment of lymphoid malignancies.
Castillo JJ; Furman M; Winer ES
Expert Opin Investig Drugs; 2012 Jan; 21(1):15-22. PubMed ID: 22112004
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of idelalisib for the treatment of indolent B-cell malignancies.
Smolewski P; Rydygier D
Expert Opin Pharmacother; 2020 Oct; 21(15):1915-1926. PubMed ID: 32686971
[TBL] [Abstract][Full Text] [Related]
13. Safety and Tolerability of Phosphatidylinositol-3-Kinase (PI3K) Inhibitors in Oncology.
Curigliano G; Shah RR
Drug Saf; 2019 Feb; 42(2):247-262. PubMed ID: 30649751
[TBL] [Abstract][Full Text] [Related]
14. Synergistic Targeting of the Regulatory and Catalytic Subunits of PI3Kδ in Mature B-cell Malignancies.
Cooney JD; Lin AP; Jiang D; Wang L; Suhasini AN; Myers J; Qiu Z; Wölfler A; Sill H; Aguiar RCT
Clin Cancer Res; 2018 Mar; 24(5):1103-1113. PubMed ID: 29246942
[No Abstract] [Full Text] [Related]
15. Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib.
Krause G; Hassenrück F; Hallek M
Drug Des Devel Ther; 2018; 12():2577-2590. PubMed ID: 30174412
[TBL] [Abstract][Full Text] [Related]
16. PI3K isoform-selective inhibitors: next-generation targeted cancer therapies.
Wang X; Ding J; Meng LH
Acta Pharmacol Sin; 2015 Oct; 36(10):1170-6. PubMed ID: 26364801
[TBL] [Abstract][Full Text] [Related]
17. Management of adverse events associated with idelalisib treatment: expert panel opinion.
Coutré SE; Barrientos JC; Brown JR; de Vos S; Furman RR; Keating MJ; Li D; O'Brien SM; Pagel JM; Poleski MH; Sharman JP; Yao NS; Zelenetz AD
Leuk Lymphoma; 2015; 56(10):2779-86. PubMed ID: 25726955
[TBL] [Abstract][Full Text] [Related]
18. Managing toxicities of phosphatidylinositol-3-kinase (PI3K) inhibitors.
Hanlon A; Brander DM
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):346-356. PubMed ID: 33275709
[TBL] [Abstract][Full Text] [Related]
19. Idelalisib: A Novel PI3Kδ Inhibitor for Chronic Lymphocytic Leukemia.
Shah A; Mangaonkar A
Ann Pharmacother; 2015 Oct; 49(10):1162-70. PubMed ID: 26185276
[TBL] [Abstract][Full Text] [Related]
20. The PI3K pathway: clinical inhibition in chronic lymphocytic leukemia.
Brown JR
Semin Oncol; 2016 Apr; 43(2):260-4. PubMed ID: 27040704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
